Introduction {#S1}
============

Traditionally, conduction through the ventricular tissue has been considered an all-or-none event scantly amenable to control. However, as early as 1953 [@B75] showed that sympathetic agonists modestly accelerated ventricle conduction. Using diverse approaches, subsequent studies also showed modest conduction increases in response to adrenergic stimulation ([@B58]; [@B16]; [@B43]; [@B4]). Of interest, the duration of the QRS complex, which reflects the total time of conduction spread through the ventricles ([@B61]), may change dynamically in the 24 h cycle ([@B60]), or in response to exercise ([@B67]). Other studies suggest that sex hormones modulate QRS duration ([@B46]; [@B62]). Interestingly, the conductivity of channels involved in the generation and transmission of the ventricular impulse (notably the cardiac Na^+^ channel, Nav1.5) may be modulated by phosphorylation, and thus are amenable to regulation by protein kinases responding to various neural and hormonal signals, in particular transmitted through activation of G-protein-coupled receptors (GPCRs) ([@B72]). Prominent in these signaling pathways are the calcium/calmodulin-dependent protein kinase II (CaMKII) ([@B34]; [@B8]; [@B27]; [@B13]) and the cAMP-activated protein kinase A (PKA) ([@B59]; [@B99]; [@B2]), collectively known as "stress" kinases for their involvement in the "fight or flight" physiological response ([@B90]; [@B91]). This mini-review will focus on very recent (and still limited) information regarding how the electrical wave propagation through ventricular chambers is regulated by stress kinases. Specifically, we will highlight a largely unknown *regional* aspect of kinase function in the ventricles, and will discuss its relevance to clinical conditions causing reduced ventricular excitability, such as the Brugada syndrome (BrS). A comprehensive review on the fundamentals of cardiac conduction can be found elsewhere ([@B82]).

Normal Ventricular Conduction Is Sustained by Constitutive Activity of CaMKII and PKA {#S2}
=====================================================================================

CaMKII, a serine/threonine-specific protein kinase regulated by the Ca^2+^/calmodulin complex ([@B47]; [@B21]), modulates the cardiac response to stress by targeting numerous ion channels and transporters ([@B9]). Importantly, CaMKII functionally regulates the three main components of cardiac excitability: Nav1.5 ([@B86]; [@B93]; [@B3]), inward-rectifier potassium channels underlying the K^+^ current I~K1~ ([@B87]), and gap junction channels formed by Connexin 43 (Cx43) proteins ([@B69]; [@B32]). Recently, CaMKII has garnered attention due to its ability to modulate ion channels in ways that favor afterdepolarizations, and for its prominent role in cardiac disease development ([@B77]). Increased activity of CaMKII \[which may occur due to CaMKII overexpression ([@B97], [@B98]) or upregulation in the failing heart ([@B5])\] alters Ca^2+^ homeostasis \[including increased Ca^2+^ entry through I~CaL~ ([@B6]); increased Ca^2+^ release through RyR ([@B90]); and increased Ca^2+^ reuptake to the SR ([@B53])\] and enhances the late sodium current (I~NaL~) ([@B86]; [@B48]), both effects promoting abnormal cellular triggered activity and arrhythmia ([@B5]; [@B85]). Whereas there is a general consensus on the direction of CaMKII regulation of cellular Ca^2+^ cycling ([@B77]), regulation of cellular excitability and conduction by CaMKII remains controversial. On the cellular level, some studies suggested that CaMKII activity favors an overall Na^+^ current (I~Na~) upregulation ([@B93]; [@B3]), while others argued that it promotes an overall I~Na~ downregulation ([@B86]). [@B93] were the first to suggest that baseline CaMKII activity is *required* for normal ventricular excitation, and that CaMKII inhibition is detrimental. The authors showed that the CaMKII blocker KN93 reduced peak I~Na~, shifted the steady-state inactivation curve to hyperpolarized values, decreased I~*NaL*~, enhanced intermediate inactivation, and delayed the recovery from fast and slow inactivation. Altered I~Na~ kinetics led to a significant suppression of the action potential upstroke velocity (d*V*/d*t*~*max*~), a measure of cellular excitability. In terms of the regulation *direction*, [@B93] results are consistent with findings by [@B3], who showed that intracellular delivery of CaMKII (CaMKIIα) to isolated guinea pig myocytes caused upregulation of I~Na~ (i.e., changes in kinetics leading to increased availability of I~Na~ under physiological conditions). However, the studies by [@B93] and [@B3] contradict the studies performed in isolated adult mouse/rabbit myocytes ([@B86]), HEK293 cells ([@B19]; [@B8]), or using simulations ([@B33]), that showed that overexpression/inhibition of CaMKII suppressed/enhanced I~Na~ availability, and inhibitors KN93 (or AIP, a peptide inhibitor) rescued CaMKII overexpression-induced detrimental effects.

CaMKII regulation of ventricular conduction in the whole heart is also controversial. [@B78] reported that a chronic reduction in CaMKII activity in mice following expression of CaMKII-inhibiting autocamtide-3-related peptide (AC3-I) caused an *increase* in conduction velocity (CV) in both RV and LV. In addition, they showed that inhibition of calmodulin, the upstream regulator of CaMKII, *increased* ventricular CV, and *reduced* arrhythmogenicity in isolated rabbit hearts ([@B78]). The improved conduction following calmodulin/CaMKII inhibition was attributed to increased localization of Cx43 in the intercalated disk ([@B78]). On the physiological level, our own studies yielded strikingly opposite outcomes ([@B89]; [@B88]; [@B94]). Specifically, inhibition of either CaMKII or calmodulin *slowed down* propagation mainly due to inducing severe conduction defects in the right ventricular outflow tract (RVOT, [Figure 1A](#F1){ref-type="fig"}, leftmost and center panels), and this was *proarrhythmic* ([Figure 1B](#F1){ref-type="fig"}; [@B89]; [@B94]). Whilst Cx43 channel function was not analyzed, CaMKII blockade reduced d*V*/d*t*~max~ both in myocytes and whole hearts ([@B88]; [@B94]), consistent with [@B93] data, and suggestive of a reduced I~Na~ availability. Moreover, CaMKII inhibition caused highly rate-dependent changes of ventricular conduction and excitability (see more below) ([@B88]; [@B94]), readily explained by altered I~Na~ inactivation ([@B93]), but not by altered localization or conductivity of Cx43. Investigating how CaMKII gain- and loss-of-function alters both myocardial active and passive properties in the same whole-heart animal model will likely resolve the controversy. We invite anyone interested to collaborate on such a study.

![**(A)** Inhibition of either CaMKII or PKA signaling leads to preferential conduction slowing in the basal RV approximately corresponding to the RVOT. Qualitatively, similar effects are produced by blockade of calmodulin, CaMKII, or PKA with W7, KN93, and H89, respectively. **(B)** With sufficient concentration and/or time of exposure, all three interventions lead to reentrant VT or VF, with the driving rotors preferentially occurring in the RVOT \[reused with permission from the American Journal of Physiology ([@B89]) and [@B94]\].](fphys-11-00086-g001){#F1}

PKA is a cAMP sensitive protein kinase which responds to beta-adrenergic receptor activation ([@B79]; [@B76]), and is inhibited by muscarinic receptor activation ([@B30]). PKA activation drives the physiological response to stress by targeting molecular components of cardiac function and excitability ([@B76]). Interestingly, CaMKII and PKA work hand in hand *upregulating* excitation--contraction coupling in response to stress ([@B29]). Consequently, and given that Nav1.5 phosphorylation sites targeted by CaMKII or PKA cluster mostly in the first intracellular linker loop of the channel ([@B49]), including a potentially shared site at Ser^571^ ([@B34]; [@B50]), we hypothesized that PKA regulates ventricular conduction similarly to CaMKII. This was subsequently confirmed ([@B94]). [Figure 1A](#F1){ref-type="fig"} (rightmost panel) illustrates how PKA blockade with H89 caused a highly non-uniform, RVOT-centric, depression of conduction, which initiated arrhythmia ([Figure 1B](#F1){ref-type="fig"}).

Our organ-level findings are generally consistent with single cell patch clamp studies indicating that PKA and/or its upstream signals (beta-agonists and cAMP) *upregulate* I~Na~ ([@B51]; [@B25]; [@B44]; [@B3]). Although some early studies suggested opposite effects ([@B64]; [@B73]), slow background shifts in I~Na~ kinetics common in isolated myocytes may have confounded those results ([@B63]). Of note, diverse mechanisms of PKA-mediated I~Na~ upregulation were proposed, including PKA-induced increase in Na^+^ channel trafficking to the sarcolemma ([@B100], [@B99]). To date, there is no cellular counterpart to our whole heart study ([@B94]) that would clarify how *inhibition* of PKA modulates I~Na~ gating. However, similarities in the conduction depression patterns elicited by CaMKII and PKA inhibition ([Figure 1](#F1){ref-type="fig"}) suggest that the underlying ionic mechanisms are also similar.

Role of Phosphatases -- A "Known Unknown" {#S3}
=========================================

In the 1980s the notion emerged that opposing actions of endogenous phosphatases and associated kinases set the basal level of membrane currents, such as the L-type inward Ca^2+^ current ([@B31]), I~K1~ ([@B40]), and connexins ([@B57]). It is suggested that type 1 and type 2A phosphatases (PP1 and PP2A) are key to regulating ion channel phosphorylation ([@B45]; [@B81]), but improved understanding is pending. A recent study by [@B20] using a PP2A phosphatase-defective transgenic mouse showed that adrenergic stimulation of myocytes induced aberrant action potentials attributed to a deficient dephosphorylation of Nav1.5 affecting I~*NaL*~. This study reported no significant difference in the fast component of I~Na~ ([@B20]).

In our experiments, administration of broad-acting phosphatase inhibitor calyculin to isolated rabbit hearts led to a small yet significant acceleration of ventricular conduction, the effect being greater in the RV than in the LV ([@B94]). This supports a phosphatase-mediated *negative* regulation of excitability, which differs from [@B20]. Given the broad action of calyculin, our data might indicate that a phosphatase other than PP2A (e.g., PP1) regulates the fast component of I~Na~.

Additional indirect evidence of the phosphatase-mediated *negative* regulation of excitability is the progressive nature of CaMKII/PKA-inhibition-mediated conduction defects (steady state after \>1 h of kinase blockade) ([@B94]). The progressive conduction deterioration is most easily explained in terms of continuing phosphatase activity amid decreased total kinase activity. Because the RV is revealed as the most vulnerable region, it is plausible that phosphorylation/dephosphorylation imbalance affects it more prominently.

Stress Kinases Regulate Ventricular Conduction in a Rate-Dependent Manner {#S4}
=========================================================================

Besides the progressive conduction deterioration caused by CaMKII and/or PKA blockade, the effect of each blocker was strongly rate dependent. Combined, these two effects resulted in a frequency-dependence which progressed with time. At short durations of drug exposure, the detrimental effect of either CaMKII or PKA blockade was noticeable only at relatively high pacing rates (short pacing intervals), but with increased exposure to drug conduction was affected even at physiological pacing rates. The detrimental effects of kinases' blockade were always largest in the basal RV (approximately corresponding to the RVOT), culminating in 2:1 conduction block, turbulence, and initiation of VF in that region at pacing intervals as long as 400 ms ([Figure 1B](#F1){ref-type="fig"}; [@B94]). Remarkably, severe conduction depression induced by either CaMKII or PKA inhibition was almost fully abolished just by prolongation of the pacing interval to \>6000 ms ([@B94]).

This result is revealing. First, it suggests that I~K1~ or Cx43 channels, the two major factors of ventricular syncytial conduction besides I~Na~, do not play a significant role in mediating adverse effects caused by stress kinases' inhibition. Even though current evidence points to CaMKII and PKA targeting both connexins ([@B15]; [@B56]; [@B69]; [@B32]) and I~K1~ ([@B24]; [@B40],[@B41],[@B42]; [@B87]), neither is known to possess time-dependent gating properties. Second, given [@B93] data, enhancement of intermediate/slow inactivation of I~Na~ emerges as the likely mechanism causing conduction abnormalities in the presence of CaMKII inhibition. Furthermore, by similarity of the CaMKII and PKA inhibition effects, we predict that PKA also regulates intermediate/slow inactivation of I~Na~, an effect not reported thus far. Lastly, the fact that long period of quiescence abolishes the effect of PKA and/or CaMKII inhibition disfavors the notion that our observed upregulation of I~Na~ by PKA and/or CaMKII is due to Na^+^ channel trafficking to the plasma membrane ([@B100]). From the perspective of Nav1.5 gating mechanisms, it remains to be understood how insufficient phosphorylation of the protein, likely at locations identified in the 1st intracellular loop ([@B49]), favors stabilization of the channel in the inactivated state.

Constitutive Activity of CaMKII and PKA in the Heart -- How Much of It? {#S5}
=======================================================================

[@B18] demonstrated that CaMKII can act as an intracellular Ca^2+^ (\[Ca^2+^\]~*i*~) transducer and activation frequency sensor *in vitro*. In line with this, using FRET-based biosensor Camui, [@B22] showed that increased activation rates (range 0--1 Hz) significantly increased CaMKII activity in isolated rabbit ventricular myocytes. Since the tested rates are much below the resting heart rate, one should expect a much higher level of CaMKII activation at the physiological baseline. In addition, even in quiescent cells, a significant activation of CaMKII produced by various neurohumoral ligands acting upon GPCR was reported ([@B22]). Thus, the normal physiological level of CaMKII activity in the heart is a complex integral of various signals. Whereas it has not yet been quantitatively assessed, the degree at which CaMKII blockade affects conduction in hearts paced at normal physiological rate and in the absence of GPCR stimulation ([@B94]), clearly indicates that the basal level of CaMKII activity is far from zero. To which extent this level is regulated by acute variations in heart rate and \[Ca^2+^\]*~*i*~*, or by phasic changes in autonomic and endocrine regulation, remains unknown and needs to be further investigated.

PKA constitutive activity is largely determined by the relationship between the half-maximal cAMP concentration required for PKA activation and the basal level of cAMP in cells. Measures of cAMP concentration yielded values around 1 μM ([@B80]; [@B35]). According to several *in vitro* studies, the cAMP concentration required for half-maximal activation of PKA is in the range 90--300 nM ([@B1]; [@B55]). Based on these estimates, PKA should be fully activated under resting conditions, precluding the possibility of a dynamic response to upstream signals acting via cAMP, which clearly contradicts fundamental physiology. Various schemes were proposed to resolve this controversy, including cAMP sequestration that renders it inactive ([@B23]), or the presence of intracellular domains in which cAMP concentration is much lower than the bulk cytosol concentration ([@B35]). Recently, [@B39] challenged the prior *in vitro* estimates of PKA sensitivity, reporting significantly higher half-maximal concentrations for the enzyme (5.2 μM cAMP) measured in intact Chinese hamster ovary cells. Upon inhibition of PKA (10 μM H89) in unstimulated cells, they found no detectable change in FRET-based PKA activity reporter signal, suggesting a negligible level of PKA activity at baseline cAMP levels. However, 10 μM H89 induced a dramatic slowing of ventricular conduction in perfused rabbit hearts, supporting the presence of robust endogenous PKA activity, even in the absence of beta-adrenergic and other neural and hormonal signals ([@B94]). Perhaps, PKA signaling is very different between ovary cells and cardiac myocytes. Since isolated hearts respond to both beta-adrenergic stimulation and stimulation of cAMP synthesis with vigorous increase in PKA activity ([@B96]), the constitutive level of PKA activity in the intact heart must be far from both inactive and fully activated state, but where it stands exactly, remains to be established.

Conduction Vulnerability in the RV: The Achilles' Heel of the Heart {#S6}
===================================================================

The spatial patterns of ventricular conduction depression induced by "stress" kinase inhibitors are unique insomuch that the RV is affected much more prominently than the LV, and within the RV the most affected region is RVOT. This pattern is remarkably similar among the kinase inhibitors KN93 and H89, as well as the calmodulin inhibitor W7 ([Figure 1A](#F1){ref-type="fig"}), suggesting a common mechanism of action.

[Figures 2A--C](#F2){ref-type="fig"} illustrate how the specific RVOT vulnerability can be explained in terms of its intrinsically reduced excitability (reflected in reduced d*V*/d*t*~max~, see [Figure 2C](#F2){ref-type="fig"} inset), compared to other ventricular regions such as the anterior--apical left ventricle (AALV) ([@B88]). The reduced excitability presumably results from the locally reduced expression levels of Nav1.5 ([@B83]; [@B11]). The fact that, despite regional differences in excitability, the impulse conduction is uniform through the ventricular chambers (see [Figure 1A](#F1){ref-type="fig"}, upper panels; see also Figures 3D--E in [@B11]) requires explanation. We believe that two factors are involved. One is that cardiac excitability operates within a wide margin of safety across which impulse conduction is robust ([Figure 2D](#F2){ref-type="fig"}). The presence of such a safety margin stems from the asymptotic relationship between action potential upstroke (d*V*/d*t*~max~) and conduction ([@B12]; [@B74]), whereby d*V*/d*t*~max~ needs to cross a critical threshold before conduction is noticeably affected ([Figure 2D](#F2){ref-type="fig"}).

![Concealed conduction vulnerability in the right ventricular outflow tract (RVOT). The left-hand part **(A--D)** illustrates the currently established static component of the phenomenon, whereas the right-hand part **(E--G)** illustrates a largely hypothetical dynamic component. **(A)** The anterior view of the heart showing RVOT and the anterior--apical left ventricle (AALV), the two regions with demonstrated significant differences in properties affecting conduction. **(B)** Compared to AALV (and possibly other ventricular regions), RVOT has a lesser expression of Nav 1.5, the pore-forming subunit of I~Na~ ([@B11]), but a larger expression of "stress" kinases PKA and CaMKII ([@B94]). **(C)** Cardiac myocytes from RVOT have reduced excitability (assessed by the maximum slope of the action potential upstroke slope, d*V*/d*t*~max~) than cardiac myocytes from AALV \[reused with permission from the American Journal of Physiology ([@B88])\]. **(D)** The theoretical non-linear relationship between excitability and conduction velocity ([@B74]) which may explain the relatively uniform conduction velocities across the ventricles ([@B94]) despite the regional differences in the expression of Nav 1.5 and excitability \[modified [@B74], with permission\]. **(E)** A diagram highlighting the dynamic nature of the phosphorylated state of Nav 1.5, which depends on the dynamic equilibrium between the sum of all kinase and phosphatase activity. Overall, little is known about the actual temporal fluctuations of Nav 1.5 phosphorylation, but such can be inferred from the fact that both PKA and CaMKII are downstream of highly dynamic autonomic and endocrine signals. **(F,G)** Physiological fluctuations of Nav 1.5 phosphorylation may lead to variations in excitability and conduction velocity \[slower conduction with less phosphorylation ([@B94])\]. While such variations are benign under normal conditions **(F)**, they may lead to acute conduction crisis and reentrant arrhythmias when I~Na~ expression is globally reduced **(G)** ([@B71]), or when the phosphorylation balance of Nav 1.5 is compromised ([@B2]) in patients with Brugada syndrome (BrS).](fphys-11-00086-g002){#F2}

The second factor is the presence of spatial heterogeneity in stress kinase-related signaling ([Figures 2A,B](#F2){ref-type="fig"}). We found that the protein expression levels of CaMKII-δ ([@B47]) and of the catalytic subunit of PKA (PKA-Cα) ([@B92]) are significantly higher in the RVOT than in the AALV ([@B94]), suggesting increased local activities of these enzymes. Others showed that the RV hemodynamic response was more sensitive to β-adrenergic stimulation than the LV ([@B36]). Additionally, RV myocytes subject to isoproterenol exhibited increased sarcomere shortening, Ca^2+^ transient amplitude, cytoplasmic cAMP accumulation, and PKA activity compared to the LV counterparts ([@B54]). These findings suggest the existence of an organ-wide program which controls local cellular signaling to maintain a specific functional profile. Whereas the physiological advantage of such an adaptation remains unclear, an apparent physiological role of stress kinases is to upregulate functional I~Na~ ([@B3]) to maintain RV excitability well within the margins of safety. The source of this heterogeneity may be linked to the distinct development origin of the RVOT ([@B10]), which has been associated to a more persistent RVOT-regional slow impulse conduction during cardiac development ([@B17]; [@B11]). Alternatively, we speculate that higher expression levels of CaMKII and PKA in RVOT could develop in response to a comparatively higher local mechanical stress caused by the distinct hemodynamic context in which RVOT operates ([@B26]). However, the physiological advantage or necessity of intrinsically reduced RVOT excitability ([@B88]) remains elusive.

Finally, the role of regional differences in the myocardial organization properties such as connexin distribution ([@B65]), fiber orientation ([@B14]), or cleft geometry ([@B38]) might be important. We should note, however, that isolated cells subject to kinase inhibitors developed depressed excitability characteristics akin to that observed in intact tissue ([@B88]), indicating that tissue architecture *is not required* for the phenomenon to develop. Additionally, the dynamic nature of the phenomenon cannot be readily ascribed to tissue architecture components which are functionally time-independent. Thus, it seems that the tissue architecture is not directly responsible for the core phenomenon of kinase inhibition-induced conduction depression. However, it may contribute to increased conduction vulnerability in the RVOT by conferring the region a narrower safety margin for conduction.

Stress Kinase Activity and the Brugada Syndrome {#S7}
===============================================

The BrS is a hereditary lethal cardiac condition associated with conduction abnormalities in the RVOT ([@B37]; [@B68]; [@B95]). Abnormal I~Na~ function likely underlies the BrS phenotype, since the majority of known mutations causing the disease affect this current ([@B7]). The ECG signature of BrS, an abnormal ST segment elevation in precordial leads, manifests intermittently ([@B84]). Circadian biases in the development of abnormal ST segment elevation ([@B28]), as well as in the initiation of VF ([@B52]), underscore the dynamic nature of BrS. Increased parasympathetic tone can also underlie the dynamic unmasking of the disease phenotype, which can be reverted by interventions that increase the sympathetic signals ([@B37]).

Conduction patterns induced by "stress" kinase inhibition ([Figure 1](#F1){ref-type="fig"}) are strikingly similar to RVOT-centric conduction defects described in BrS patients ([@B95]). A prevailing paradox is that the permanent nature of dysfunctional Nav1.5 mutations afflicting BrS patients is typically associated to intermittent or lacking phenotypes. We speculate that the intermittent display of BrS phenotype may in part depend on dynamic fluctuations in stress kinases' activity. Supporting this, half-maximal blockade of I~Na~ with TTX \[which is similar to the degree of I~Na~ loss-of-function in some BrS models ([@B66]; [@B70])\] caused only a uniform slowing of conduction, while a subsequent short exposure to CaMKII inhibitor KN93 disproportionally slowed RV conduction, bringing about BrS-like phenotype ([@B94]). We submit that following kinase activity fluctuations ([Figure 2E](#F2){ref-type="fig"}), ventricular excitability is dynamically shifted back-and-forth within the limits of safe conduction, which are wide in healthy hearts ([Figure 2F](#F2){ref-type="fig"}), but narrower in hearts affected by the BrS ([Figure 2G](#F2){ref-type="fig"}). When this limit is breached, conduction in the RVOT fails first, and VF initiates in a manner similar to that observed during kinase inhibition ([Figure 2G](#F2){ref-type="fig"}, right panel). Whereas there are no known cases of BrS involving CaMKII signaling, a family with BrS bore a SCN5A mutation in a PKA consensus phosphorylation site, which effectively disrupted positive regulation of I~Na~ by PKA ([@B2]). Overall, the role of stress kinase signaling in BrS remains poorly understood and definitely merits further investigation.

Conclusion {#S8}
==========

Because of an intrinsically reduced safety margin for conduction in the RV/RVOT, the constitutive activity of both CaMKII and PKA is *required* for normal ventricular conduction. Consequently, any intervention decreasing activity of these kinases is potentially pro-arrhythmic and life-threatening. Further, any condition leading to additional reduction in the RV excitability (BrS, ischemia, and electrolyte imbalance) bears increased risk. Normal ventricular conduction hinges on the delicate balance of phosphorylation/dephosphorylation, which is a result of a very complex and highly dynamic summation of upstream signals mediated through nervous and endocrine regulation, as well as circadian rhythms. Whereas a wealth of knowledge has been accumulated at the level of molecular mechanisms involved in regulation of cardiac ionic channels by phosphorylation, there is a deficiency in translating these mechanisms to the level of whole-heart physiology and pathophysiology. We hope that this mini-review will stimulate investigations to bridge this gap.
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